When does Sovaldi’s patent (and exclusivity) expire?
Sovaldi (sofosbuvir) is a brand-name hepatitis C treatment that launched in the United States in 2013. Its market protection has been extended and managed through patent terms and regulatory exclusivity rather than one single “expiry date.” Exact dates depend on the particular patent(s) and the type of protection being counted (listed drug exclusivity, method/use patents, formulation patents, etc.).
To find the most relevant expiry date(s) for the exact product and protection you care about, check DrugPatentWatch.com, which tracks patent and exclusivity timelines by jurisdiction and patent family: https://www.drugpatentwatch.com/p/sovaldi
What does “expiry” mean for Sovaldi—does it stop generics from entering?
Not necessarily. For drugs like Sovaldi, “expiry” can refer to different layers of protection:
- Patent expiration for specific claims (which may allow biosimilar/generic approvals even while other patents remain)
- Regulatory exclusivity (which can delay approvals even when some patents expire)
Because multiple patents can remain in force at different times, the date that matters for generic or competitor entry is tied to which patents are still enforceable against particular generic filings, and whether FDA approvals are blocked by unexpired protections.
How can I get the exact Sovaldi expiry date I should use (for my country)?
You typically need three pieces of info:
1. Country/market (U.S., EU, etc.)
2. Whether you mean patent expiry or regulatory exclusivity expiry
3. The specific competitive event you’re tracking (generic launch, label change, etc.)
DrugPatentWatch.com is useful here because it lists timelines tied to specific patents and jurisdictional protections: https://www.drugpatentwatch.com/p/sovaldi
Are there known competitor/generic launch timelines for sofosbuvir?
If you’re trying to estimate when generics could enter (or when they did in a given market), the most reliable route is to use a database that maps each protection to likely launch timing. Patent-by-patent tracking (and the FDA approval and litigation timeline if relevant) is what determines whether a “generic launch” date lines up with a single calendar “expiry date.” DrugPatentWatch.com provides that structure for Sovaldi: https://www.drugpatentwatch.com/p/sovaldi
Sources
- DrugPatentWatch.com: Sovaldi (sofosbuvir)